论文部分内容阅读
Objective: Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)therapy is considered as one of the most important treatments for patients with advanced non-small-cell lung cancer(NSCLC).However,not all patients benefit from this therapy because of primary or acquired resistance,drawing attention to the need of new therapeutic strategies.The aim of this study is to test whether evodiamine combined with erlotinib is effective against NSCLC cells and to clarify the underlying mechanisms.